FDMT · 4D Molecular Therapeutics, Inc.

The Board of Directors appointed Kristian Humer, age 51, as Principal Accounting Officer effective March 25, 2026. He succeeds Ashoo Gupta, who continues to serve as Vice President, Finance and Controller. Mr. Humer has served as the Company's Chief Financial Officer and Principal Financial Officer since November 2025. His prior experience includes serving as Chief Financial Officer at Foghorn Therapeutics, Inc. from April 2024 to November 2025, and as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc. from July 2021 to September 2023. He also held various roles at Citigroup Global Markets Inc., including Managing Director in the Healthcare Investment Banking Group. Mr. Humer holds an MBA from Duke University and a BA in Accounting & Economics from the University of Reading.